Division of Vascular and Endovascular Surgery, Harvard Medical School, Massachusetts General Hospital, Boston, MA.
Division of Vascular and Endovascular Surgery, Harvard Medical School, Massachusetts General Hospital, Boston, MA.
J Vasc Surg. 2022 Jul;76(1):248-254. doi: 10.1016/j.jvs.2022.02.045. Epub 2022 Mar 8.
In this multi-institutional series, we aimed to determine the incidence, risk factors, and long-term outcomes of graft infection in patients post-femoropopliteal bypass.
A multi-institutional database was retrospectively queried for all femoropopliteal bypass procedures from 1995 through 2020. Cumulative incidence function estimated the long-term rate of bypass graft infection (BGI), and the Fine-Gray model was used to determine independent risk factors for BGI to account for death as a competing risk.
Over the 25-year period, 1315 femoral popliteal bypasses were identified with a median follow-up of 2.89 years (interquartile range, 0.75-6.55 years). BGI was diagnosed in 34 patients (2.6%). BGI occurred between 9 days and 11.2 years postoperatively, with a median of 109 days. Estimated 1- and 5-year incidence of BGI was 2.1% (95% confidence interval [CI], 1.4%-3.1%) and 2.8% (95% CI, 1.9%-3.9%), respectively. Medical comorbidities, indications for bypass, and popliteal bypass targets (above- vs below-knee) were similar between patients with BGI and all patients (P = not significant for each). Patients with BGI were more frequently complicated by postoperative hematoma (14.7% vs 3.7%), superficial wound infection (38.2% vs 19.2%), lymphocele/lymphorrhea (8.8% vs 2.1%), and 30-day readmission rates (47.1% vs 21.3%) (P < .05 for each). Most commonly isolated pathogens were Staphylococcus aureus (n = 19; 55.9%) and polymicrobial cultures (n = 5; 14.7%). Reoperation for BGI involved incision and drainage (n = 7; 20.6%), graft excision without reconstruction (n = 12; 35.3%), graft excision with in-line reconstruction (n = 11; 32.4%), and graft excision with extra-anatomic reconstruction (n = 2; 5.9%). Nine patients with BGI (26.5%) ultimately required major amputation. Prosthetic bypass (subdistribution hazard ratio [SHR], 3.73; 95% CI, 1.64-8.51; P = .002), postoperative hematoma (SHR, 3.44; 95% CI, 1.23-9.61; P = .018), and 30-day readmission (SHR, 2.75; 95% CI, 1.27-5.44; P = .010) were independently associated with BGI. One-year amputation-free survival was 50% (95% CI, 31.9%-65.7%) after BGI.
BGI is a rare complication of femoral-popliteal bypass with significant morbidity. Graft infection is associated with the use of prosthetic grafts, postoperative hematoma, and unplanned hospital readmission. Mitigation of these risk factors may decrease the risk of this dreaded complication.
在这项多机构系列研究中,我们旨在确定股腘旁路术后移植感染的发生率、风险因素和长期结局。
回顾性查询了 1995 年至 2020 年期间所有股腘旁路手术的多机构数据库。累积发生率函数估计了旁路移植感染(BGl)的长期发生率,Fine-Gray 模型用于确定 BGl 的独立风险因素,以考虑死亡作为竞争风险。
在 25 年期间,确定了 1315 例股腘旁路手术,中位随访时间为 2.89 年(四分位间距,0.75-6.55 年)。34 例患者(2.6%)诊断为 BGl。BGl 发生在术后 9 天至 11.2 年,中位时间为 109 天。估计的 1 年和 5 年 BGl 发生率分别为 2.1%(95%置信区间,1.4%-3.1%)和 2.8%(95%置信区间,1.9%-3.9%)。BGl 患者与所有患者(P 均不显著)的合并症、旁路手术指征以及旁路目标(膝上与膝下)相似。BGl 患者术后血肿(14.7%比 3.7%)、浅表伤口感染(38.2%比 19.2%)、淋巴囊肿/淋巴漏(8.8%比 2.1%)和 30 天再入院率(47.1%比 21.3%)更常见(P 均<.05)。最常见的分离病原体是金黄色葡萄球菌(n=19;55.9%)和混合培养物(n=5;14.7%)。BGl 的再手术包括切开引流(n=7;20.6%)、切除移植物而不重建(n=12;35.3%)、切除移植物并行原位重建(n=11;32.4%)和切除移植物行异位重建(n=2;5.9%)。9 例 BGl 患者(26.5%)最终需要进行大截肢。假体重建(亚分布危险比 [SHR],3.73;95%置信区间,1.64-8.51;P=.002)、术后血肿(SHR,3.44;95%置信区间,1.23-9.61;P=.018)和 30 天再入院(SHR,2.75;95%置信区间,1.27-5.44;P=.010)与 BGl 独立相关。BGl 后 1 年无截肢生存率为 50%(95%置信区间,31.9%-65.7%)。
BGl 是股腘旁路术后罕见的并发症,具有显著的发病率。移植物感染与使用假体移植物、术后血肿和计划外医院再入院有关。减轻这些风险因素可能会降低这种可怕并发症的风险。